Haematologica (Dec 2007)

Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia

  • Yuko Osugi,
  • Hiroshi Yagasaki,
  • Masahiro Sako,
  • Yoshiyuki Kosaka,
  • Takashi Taga,
  • Tsuyoshi Ito,
  • Masuji Yamamoto,
  • Akira Ohara,
  • Takeyuki Sato,
  • Junichi Mimaya,
  • Ichiro Tsukimoto,
  • Seiji Kojima,
  • the Japan Childhood Aplastic Anemia Study Group

DOI
https://doi.org/10.3324/haematol.11359
Journal volume & issue
Vol. 92, no. 12

Abstract

Read online

We analyzed the outcomes of 44 children with hepatitis associated aplastic anemia (HAA) who received immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CsA). Fourteen (31.8%) patients achieved complete response and 17 (38.6%) achieved partial response, for an overall response rate of 70.4% after 6 months. Seven non-responders received bone marrow transplantation from an HLA-matched unrelated donor and 6 out of 7 are alive. The probability of overall survival at 10 years was 88.3±4.9%, which supports the role of IST with ATG and CsA as treatment of choice for children with HAA without an HLA identical sibling donor.